The role of urate and xanthine oxidase in vascular oxidative stress: Future directions

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 799-803

  George, Jacob ^a   Struthers, Allan ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Allopurinol; Febuxostat; Urate; Vascular oxidative stress

Indexed keywords

ALLOPURINOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FEBUXOSTAT; HEPARIN; HYDROGEN PEROXIDE; LOSARTAN; OXIPURINOL; URATE; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SHORT SURVEY; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 77949478632     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s5701     Document Type: Short Survey

References (52)

1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87(10):840-844.
2. Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J. 2003;146(2):218-226.
3. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104(22):2673-2678.
4. Kobayashi N, DeLano FA, Schmid-Schonbein GW. Oxidative stress promotes endothelial cell apoptosis and loss of microvessels in the spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 2005;25(10):2114-2121.
5. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 2002;106(24):3073-3078.
6. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74(6):1141-1148.
7. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91(3A):7A-11A.
8. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555(Pt 3):589-606.
9. Hille R, Massey V. Studies on the oxidative half-reaction of xanthine oxidase. J Biol Chem. 1981;256(17):9090-9095.
10. George J, Carr E, Davies J, Belch JJF, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508-2516.
11. Khan F, George J, Wong K, McSwiggan S, Struthers AD, Belch JJ. Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc Ther. 2008;26(4):247-252.
12. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marban E, Weiss RG. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol. 2006;290(2):H837-H843.
13. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164(14):1546-1551.
14. Parmley LF, Mufti AG, Downey JM. Allopurinol therapy of ischemic heart disease with infarct extension. Can J Cardiol. 1992;8(3):280-286.
15. Waring WS, McKnight JA, Webb DJ, Maxwell SRJ. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabete. 2006;55:3127-3132.
16. Yiginer O, Ozcelik F, Inanc T, et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol. 2008;97(5):334-340.
17. Christie GA, Lucas C, Bateman DN, Waring WS. Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses. Eur J Clin Pharmacol. 2006;62(12):989-993.
18. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68(3):1190-1198.
19. Graham S, Day RO, Wong H, et al. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol. 1996;41(4):299-304.
20. Turnheim, Kr ivanek, Oberbauer . Pharmacokinet ics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol. 1999;48(4):501-509.
21. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003;107(10):1383-1389.
22. Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005;26(15):1544-1550.
23. Kannel WB, Abbott RD. A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study. Am Heart J. 1986;111(2):391-397.
24. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141(3):334-341.
25. Gosse P. Left ventricular hypertrophy - the problem and possible solutions. J Int Med Res. 2005;33 Suppl 1:3A-11A.
26. Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115(18):2418-2425.
27. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140(6):848-856.
28. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97(1):48-54.
29. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens. 2002;15(12):1021-1028.
30. Okin PM, Devereux RB, Harris KE, et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 2007;50(5):984-990.
31. Okin PM, Wachtell K, Devereux RB, et al. Combination of the Electrocardiographic Strain Pattern and Albuminuria for the Prediction of New-onset Heart Failure in Hypertensive Patients: The LIFE Study. Am J Hypertens. 2008.
32. Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation. 2007;116(7):700-705.
33. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49(2):241-248.
34. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002;34(4):379-388.
35. George J, Struthers A. High dose allopurinol dramatically improves endothelial function beyond urate lowering and is a powerful antioxidant in chronic heart failure. Eur J Heart Failure. 2006;5(1):92.
36. Hashimoto J, Imai Y, O'Rourke MF. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Am J Hypertens. 2007;20(4):378-384.
37. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart. 2005;91(6):749-753.
38. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114.
39. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
40. Lustberg ME. Febuxostat versus allopurinol for gout. N Engl J Med. 2006;354(14):1532-1533; author reply 1532-1533.
41. Gelber AC. Febuxostat versus allopurinol for gout. N Engl J Med. 2006;354(14):1532-1533; author reply 1532-1533.
42. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301-2309.
43. Galbusera C, Orth P, Fedida D, Spector T. Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol. 2006.
44. Massey V, Komai H, Palmer G, Elion GB. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem. 1970;245(11):2837-2844.
45. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem. 2002;9(2):195-217.
46. Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. Proc Natl Acad Sci U S A. 1988;85(11):4046-4050.
47. Kogler H, Fraser H, McCune S, Altschuld R, Marban E. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res. 2003;59(3):582-592.
48. Baldus S, Koster R, Chumley P, et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med. 2005;39(9):1184-1190.
49. Cleland JGF, Coletta AP, Clark AL. Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail. 2006;8(7):764-766.
50. George J, Struthers A. The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. J Am Coll Cardiol. 2009;53(25):2405.
51. Villaba L. Oxypurinol for Symptomatic Gout in Allopurinol Intolerant Patients: Arthritis Advisory Committee Meeting. URL www.fda.gov/OHRMS/DOCKETS/ AC/04/slides/2004-4044S1-05-FDA-Villalba.ppt. Accessed June 2, 2004.
52. Adachi T, Fukushima T, Usami Y, Hirano K. Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. Biochem J. 1993;289 (Pt 2):523-527.